calithera
biosciences
arginase
inhibitor
trial
progress
poster
presented
north
american
cystic
fibrosis
virtual
conference
south
san
francisco
globe
newswire
calithera
biosciences
nasdaq
cala
clinical
stage
biotechnology
company
focused
discovering
developing
novel
drugs
treatment
cancer
diseases
today
announced
poster
detailing
trial
design
phase
study
company
arginase
inhibitor
presented
today
north
american
cystic
fibrosis
nacfc
virtual
conference
randomized
multiple
ascending
study
exploring
versus
placebo
adults
cystic
fibrosis
chronic
infection
pseudomonas
aeruginosa
stable
cystic
fibrosis
medications
including
cystic
fibrosis
transmembrane
conductance
regulator
cftr
modulators
study
evaluating
safety
pharmacokinetics
pharmacodynamics
biological
activity
four
dose
cohorts
versus
placebo
enrollment
study
ongoing
calithera
expects
share
interim
data
poster
presentation
includes
preclinical
study
results
suggest
significantly
improved
lung
function
reduced
pseudomonas
aeruginosa
units
models
arginase
inhibition
resulted
improved
central
airway
resistance
cftr
knockout
mice
decreased
lung
infection
wild
type
mice
infected
pseudomonas
aeruginosa
first
arginase
inhibitor
evaluated
treatment
cystic
fibrosis
said
susan
molineaux
phd
president
chief
executive
officer
calithera
remains
significant
need
investment
therapeutic
innovations
cystic
fibrosis
based
strong
mechanistic
rationale
optimistic
potential
arginase
inhibition
treatment
devastating
title
phase
randomized
trial
evaluate
patients
cystic
fibrosis
poster
first
author
joel
mermis
university
kansas
medical
center
copy
poster
available
publications
section
calithera
calithera
biosciences
biopharmaceutical
company
pioneering
discovery
development
targeted
therapies
disrupt
cellular
metabolic
pathways
preferentially
block
tumor
cells
enhance
activity
driven
commitment
rigorous
science
passion
improving
lives
people
impacted
cancer
diseases
calithera
advancing
pipeline
oral
therapeutics
meaningfully
expand
treatment
options
available
patients
calithera
headquartered
south
san
francisco
california
information
calithera
please
visit
forward
looking
statements
statements
contained
press
release
regarding
matters
historical
facts
statements
within
meaning
private
securities
litigation
reform
act
words
may
expect
anticipate
estimate
intend
poised
similar
expressions
well
words
expressions
referencing
future
events
conditions
circumstances
intended
identify
statements
statements
include
related
calithera
clinical
trials
clinical
commercial
potential
product
candidates
presentation
interim
data
randomized
trial
cystic
fibrosis
patients
impact
patients
cystic
fibrosis
statements
subject
risks
uncertainties
actual
results
may
differ
materially
expressed
implied
statements
potential
product
candidates
calithera
develops
may
progress
clinical
development
receive
required
regulatory
approvals
within
expected
timelines
calithera
clinical
trials
may
confirm
safety
potency
product
characteristics
described
assumed
press
release
product
candidates
may
beneficial
patients
successfully
commercialized
addition
pandemic
may
result
delays
calithera
studies
trials
failure
meet
expectations
respect
foregoing
matters
may
negative
effect
calithera
stock
price
additional
information
concerning
risk
factors
affecting
calithera
business
found
calithera
periodic
filings
securities
exchange
commission
statements
guarantees
future
performance
speak
date
hereof
except
required
law
calithera
disclaims
obligation
update
statements
reflect
future
events
circumstances
source
calithera
biosciences
inc
contacts
investor
relations
jennifer
mcnealey
calithera
ir
media
michele
parisi
sam
brown
micheleparisi
